Skip to search formSkip to main contentSkip to account menu

purvalanol A

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purvalanol A is a highly selective inhibitor of Cdc2 [also known as cyclin-dependent kinase 1 (CDK1)]. Taxol is an anti-tumor… 
2016
2016
Abstract 1. Purine cyclin-dependent kinase inhibitors have recently been recognised as promising candidates for the treatment of… 
2015
2015
Objectives: This project aimed to investigate effects of purvalanol A on imatinib-sensitive and -insensitive chronic myeloid… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Akt is a serine/threonine kinase and an essential… 
2013
2013
Cyclin-dependent kinase inhibitors (CDKi) have high potential applicability in anticancer therapy, but various aspects of their… 
2005
2005
Several recent findings indicate that intensity of neurogenesis in adult brain might be regulated by enzymes involved in the cell… 
Highly Cited
2004
Highly Cited
2004
Survivin is expressed in most tumor cells and has been associated with both anti-apoptosis and mitotic progression. However, the…